Advertisement

Dermatology and Therapy

, Volume 8, Issue 2, pp 327–327 | Cite as

Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab

  • Sebastian Spindeldreher
  • Bernard Maillère
  • Evelyne Correia
  • Maxime Tenon
  • Anette Karle
  • Philip Jarvis
  • Frank Kolbinger
Open Access
Author Correction
  • 1.6k Downloads

Author Correction to: Dermatol Ther (Heidelb) (2018) 8:57–68  https://doi.org/10.1007/s13555-018-0220-y

In the original publication, information regarding “ustekinumab” was incorrectly published under the Methods section. The correct information in the section “Antibodies and Control Protein” should be “(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)”. Infliximab, which is mentioned in that section, was not used in the study.

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright information

© The Author(s) 2018

Authors and Affiliations

  • Sebastian Spindeldreher
    • 1
  • Bernard Maillère
    • 2
  • Evelyne Correia
    • 2
  • Maxime Tenon
    • 2
  • Anette Karle
    • 3
  • Philip Jarvis
    • 1
  • Frank Kolbinger
    • 1
  1. 1.Novartis Institutes for BioMedical ResearchNovartis Pharma AGBaselSwitzerland
  2. 2.CEA-Saclay, Institut Frédéric Joliot, SIMOPROUniversité Paris-SaclayGif-Sur-YvetteFrance
  3. 3.Integrated Biologics Profiling Unit, Immunogenicity Risk AssessmentNovartis Pharma AGBaselSwitzerland

Personalised recommendations